Enterprise Value to EBITDA Ratio: Notable Labs, Ltd. (NTBL)
Notable Labs, Ltd. (NTBL) is implementing precision oncology by selecting therapies through the analysis of a patient's live cells. This EV/EBITDA price chart, which serves as confirmation of the market valuation, is fixed at . Management must now demonstrate its operational capabilities following the asset merger, as the transparency of future prospects remains moderate. Speculative potential is tied to chemotherapy software, which requires regulatory approval and external financing.
notablelabs.com - analytical breakdowns and key metrics (NTBL)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
NTBL - Company Net Income|Expected Profit Notable Labs, Ltd.|NTBL - Price to Earnings Ratio|Forward P/E Multiple Notable Labs, Ltd.|NTBL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Notable Labs Corp|NTBL - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Notable Labs|NTBL - Earnings per share for the last twelve months|Quarterly EPS earnings growth notablelabs.com|NTBL - Earnings growth in current year|Earnings growth forecast for next year Notable Labs, Ltd.
Initial company analysis:Notable Labs Inc. (NTBL)
The innovative potential of the Notable Labs, Ltd. (NTBL) oncology platform requires validation through operational efficiency following the asset merger. By tracking changes in the EV/EBITDA ratio, investors assess the business value inclusive of net debt relative to earnings before interest, taxes, depreciation, and amortization. This metric reveals whether the company is overvalued, allowing a distinction between real value growth and speculative volatility within this capital-intensive sector.
Competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|delcath.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL: Enterprise Value to EBITDA Ratio|Accuray, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|CTOR (Citius Oncology) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FATE (Fate Pharma)|EV/EBITDA Multiple WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSTX (OS Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|EV/EBITDA Multiple Artiva|EV/EBITDA Multiple ANL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VERU (Veru Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Total Company Value to Operating Income Before Depreciation Ratio Xilio Therapeutics Inc (XLO)|RENB: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MURA (Mural Oncology plc)|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OKUR (OnKure Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio GDTC|CRIS (Curis Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APLM|tharimmune.com - Enterprise Value to Operating Income Before Depreciation|Advanced Biomed - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Genprex Inc. (GNPX)|CLDI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SBFM (sunshinebiopharma.com) - Enterprise Value to Operating Income Before Depreciation|XBIO (xeneticbio.com) - Enterprise Value to EBITDA Ratio|SLRX: Enterprise Value to Operating Income Before Depreciation Ratio|PPBT (Purple Biotech Ltd.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AONC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BeOne Medicines (BGNE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CKPT (Checkpoint Therapeutics Inc)|EV/EBITDA Multiple ELEV (Elevation Oncology)|ICAD - Enterprise Value to EBITDA Ratio|Ikena - EV/EBITDA Multiple|VIRX - EV/EBITDA Multiple|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation NAYA|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
